Skip to main content
SpringerLink
Log in

Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Cortistatin (CST-14, Pro-c[Cys-Lys- Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys]-Lys- NH2), a neuropeptide member of the SRIH family, binds to all 5 SRIH receptor (sst) subtypes, but also possesses a significant binding affinity to GH secretagogue receptors (GHS-R), which have been reported to mediate the antiproliferative activity of GHS on thyroid cancer cells. The effect of CST-14 on cell proliferation was studied in 3 different human thyroid carcinoma cell lines of follicular origin (N-PAP, WRO, ARO) and in one thyroid medullary carcinoma cell line (TT). CST-14 1 μM determined a significant inhibition of cell proliferation in TT, N-PAP and WRO cells and this effect was dose-dependent and more pronounced than that displayed by SRIH-14 (Ala- Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr- Ser-Cys]-OH) treatment. To a minor extent, CST- 14, but not SRIH-14, also temporary inhibited ARO cell proliferation. By immunofluorescence, sst2, sst3 and sst5 have been demonstrated in TT cells, whereas types 3 and 5 only were expressed in N-PAP and WRO cells, and no sst subtype was found in ARO cells. The presence of both GHS-R1a and 1b mRNA has been studied and demonstrated in the TT medullary carcinoma cell line, whereas follicular derived cell lines were already known to express GHS binding sites. Addition of EP-80874 (D-Mrp-c[D-CyspyridilalanyI3- D-Trp-Lys-Val-Cys]-Mrp-NH2), a synthetic peptide that binds to SRIH and GHS-R, completely abolished the antiproliferative effects of CST-14 or SRIH-14 on sst/GHS-R positive thyroid carcinoma cell lines (WRO, N-PAP and TT). EP-80874 was also able to antagonize the inhibitory activity of CST-14 on the growth of cells (ARO) expressing GHS-R but not sst. Taken together, these data firstly demonstrate that EP- 80874 has a mixed SRIH/CST antagonist activity and suggest that the oncostatic effect of CST-14 on thyroid cancer cells could be mediated by both sst and/or GHS-R.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Veber D.F., Holly F.W., Nutt R.F., et al. Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature 1979, 280: 512–514.

    Article  CAS  PubMed  Google Scholar 

  2. de Lecea L., Ruiz-Lozano P., Danielson P.E., et al. Cloning, mRNA expression, and chromosomal mapping of mouse and human preprocortistatin. Genomics 1997, 42: 499–506.

    Article  PubMed  Google Scholar 

  3. Spier A.D., de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res. Rev. 2000, 33: 228–241.

    Article  CAS  PubMed  Google Scholar 

  4. Vasilaki A., Lanneau C., Dournaud P., et al. Cortistatin affects glutamate sensitivity in mouse hypothalamic neurons through activation of SSTR2 somatostatin receptor subtype. Neuroscience 1999, 88: 359–364.

    Article  CAS  PubMed  Google Scholar 

  5. Deghenghi R., Papotti M., Ghigo E., Muccioli G. Cortistatin, but not somatostatin, binds to growth hormone secretagogue receptors of human pituitary gland. J. Endocrinol. Invest. 2001, 24: RC1–3.

    Article  CAS  PubMed  Google Scholar 

  6. Zatelli M.C., Tagliati F., Taylor J.E., et al. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J. Clin. Endocrinol. Metab. 2001, 86: 2161–2169.

    CAS  PubMed  Google Scholar 

  7. Ain K.B., Taylor K.D., Tofiq S., Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 1997, 82: 1857–1862.

    CAS  PubMed  Google Scholar 

  8. Ain K.B., Taylor K.D. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J. Clin. Endocrinol. Metab. 1994, 78: 1097–1102.

    CAS  PubMed  Google Scholar 

  9. Cassoni P., Papotti M., Catapano F., et al. Specific binding sites for synthetic growth hormone secretagogues in nontumoral and neoplastic human thyroid tissue. J. Endocrinol. 2000, 165: 139–146.

    Article  CAS  PubMed  Google Scholar 

  10. Hoelting T., Duh Q.Y., Clark O.H., Herfarth C. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J. Clin. Endocrinol. Metab. 1996, 81: 2638–2641.

    CAS  PubMed  Google Scholar 

  11. Deghenghi R., Papotti M., Ghigo E., Muccioli G., Locatelli V. Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormonereleasing peptide receptor in the human pituitary gland. Endocrine 2001, 14: 29–33.

    Article  CAS  PubMed  Google Scholar 

  12. Papotti M., Croce S., Bellò M., et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virch. Arch. 2001, in press.

    Google Scholar 

  13. Korbonits M., Bustin S.A., Kojima M., et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J. Clin. Endocrinol. Metab. 2001, 86: 881–887.

    CAS  PubMed  Google Scholar 

  14. von Zastrow M. Endocytosis and down-regulation of G protein- coupled receptors. Parkinsonism Relat. Disord. 2001, 7: 265–271.

    Article  Google Scholar 

  15. Siehler S., Seuwen K., Hoyer D. [125I]Tyr10-cortistatin14 labels all five somatostatin receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 357: 483–489.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences and Oncology, University of Turin, Via Santenà 7, 10126, Turin, Italy

    P. Cassoni, T. Marrocco, M. Volante, E. Allia & M. Papotti

  2. Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, Turin, Italy

    G. Muccioli

  3. Department of Internal Medicine, University of Turin, Turin, Italy

    E. Ghigo

  4. Europeptides, Argenteuil, France

    R. Deghenghi

Authors
  1. P. Cassoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Muccioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Marrocco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Volante
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Allia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Ghigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Deghenghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Papotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Cassoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cassoni, P., Muccioli, G., Marrocco, T. et al. Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin. J Endocrinol Invest 25, 362–368 (2002). https://doi.org/10.1007/BF03344019

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344019

Key-words

Search

Navigation